CN110291083B - Magl抑制剂的结晶形式 - Google Patents

Magl抑制剂的结晶形式 Download PDF

Info

Publication number
CN110291083B
CN110291083B CN201780083644.3A CN201780083644A CN110291083B CN 110291083 B CN110291083 B CN 110291083B CN 201780083644 A CN201780083644 A CN 201780083644A CN 110291083 B CN110291083 B CN 110291083B
Authority
CN
China
Prior art keywords
compound
crystalline
patient
pyrrolidin
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780083644.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110291083A (zh
Inventor
谢丽尔·A·格莱斯
托德·K·琼斯
库尔特·G·格林姆
杰奎琳·洛拉尼·布莱克曼
钱宁·罗德尼·比尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Lingbei La Jolla Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS, Lingbei La Jolla Research Center filed Critical H Lundbeck AS
Priority to CN202210681321.7A priority Critical patent/CN115093382A/zh
Publication of CN110291083A publication Critical patent/CN110291083A/zh
Application granted granted Critical
Publication of CN110291083B publication Critical patent/CN110291083B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780083644.3A 2016-11-16 2017-11-15 Magl抑制剂的结晶形式 Expired - Fee Related CN110291083B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210681321.7A CN115093382A (zh) 2016-11-16 2017-11-15 Magl抑制剂的结晶形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210681321.7A Division CN115093382A (zh) 2016-11-16 2017-11-15 Magl抑制剂的结晶形式

Publications (2)

Publication Number Publication Date
CN110291083A CN110291083A (zh) 2019-09-27
CN110291083B true CN110291083B (zh) 2022-06-17

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780083644.3A Expired - Fee Related CN110291083B (zh) 2016-11-16 2017-11-15 Magl抑制剂的结晶形式
CN202210681321.7A Pending CN115093382A (zh) 2016-11-16 2017-11-15 Magl抑制剂的结晶形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210681321.7A Pending CN115093382A (zh) 2016-11-16 2017-11-15 Magl抑制剂的结晶形式

Country Status (38)

Country Link
US (2) US11142517B2 (cg-RX-API-DMAC7.html)
EP (2) EP3541807B1 (cg-RX-API-DMAC7.html)
JP (2) JP7042548B2 (cg-RX-API-DMAC7.html)
KR (1) KR102508739B1 (cg-RX-API-DMAC7.html)
CN (2) CN110291083B (cg-RX-API-DMAC7.html)
AU (1) AU2017361257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019010003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043610A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001340A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019005045A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190242A (cg-RX-API-DMAC7.html)
CY (1) CY1124870T1 (cg-RX-API-DMAC7.html)
DK (1) DK3541807T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000120A (cg-RX-API-DMAC7.html)
EA (1) EA201991086A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19035171A (cg-RX-API-DMAC7.html)
ES (2) ES2966939T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20237559B (cg-RX-API-DMAC7.html)
HR (2) HRP20211863T1 (cg-RX-API-DMAC7.html)
HU (2) HUE056973T2 (cg-RX-API-DMAC7.html)
IL (1) IL266548A (cg-RX-API-DMAC7.html)
JO (1) JOP20190109B1 (cg-RX-API-DMAC7.html)
LT (1) LT3541807T (cg-RX-API-DMAC7.html)
MA (2) MA58133B1 (cg-RX-API-DMAC7.html)
MX (2) MX389459B (cg-RX-API-DMAC7.html)
MY (1) MY199386A (cg-RX-API-DMAC7.html)
NI (1) NI201900053A (cg-RX-API-DMAC7.html)
PE (1) PE20191239A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501068A1 (cg-RX-API-DMAC7.html)
PL (2) PL3964503T3 (cg-RX-API-DMAC7.html)
PT (1) PT3541807T (cg-RX-API-DMAC7.html)
RS (2) RS65016B1 (cg-RX-API-DMAC7.html)
SI (1) SI3541807T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100675T1 (cg-RX-API-DMAC7.html)
TN (1) TN2019000151A1 (cg-RX-API-DMAC7.html)
UA (1) UA124585C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018093953A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903093B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2982694T3 (es) 2012-01-06 2024-10-17 H Lundbeck As Compuestos de carbamato para su uso en tratamiento
BR112017024253A2 (pt) 2015-05-11 2018-07-24 Abide Therapeutics Inc métodos de tratamento de inflamação ou dor neuropática.
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
HUE056973T2 (hu) 2016-11-16 2022-04-28 H Lundbeck As MAGL inhibitor kristályos formája
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
JOP20190262B1 (ar) 2017-05-23 2023-09-17 H Lundbeck As مثبطات بيرازول magl
EP3675847B1 (en) 2017-08-29 2023-07-12 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
JOP20200276A1 (ar) * 2018-05-15 2020-11-02 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US20210309669A1 (en) * 2018-07-19 2021-10-07 Pfizer Inc. Heterocyclic Spiro Compounds As MAGL Inhibitors
WO2020035424A1 (en) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
MX2021008865A (es) * 2019-01-25 2021-10-26 H Lundbeck As Inhibidores de magl para usarse para tratar enfermedades antecedentes.
EP4058431A4 (en) * 2019-11-15 2023-11-15 H. Lundbeck A/S Crystalline forms of a magl inhibitor
MX2022013224A (es) 2020-04-21 2022-11-14 H Lundbeck As Sintesis de un inhibidor de la monoacilglicerol lipasa.
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
KR20240128870A (ko) 2021-12-29 2024-08-27 싸이 테라퓨틱스, 인크. 모노아실글리세롤 리파아제(magl) 억제
AU2023264787A1 (en) 2022-05-04 2024-10-31 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159581A (zh) * 2012-01-06 2014-11-19 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
WO1993009785A1 (en) 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2180548T3 (es) 1992-10-16 2003-02-16 Nippon Shinyaku Co Ltd Metodo de obtencion de matrices de cera.
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2001225816B2 (en) 2000-12-18 2005-10-13 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
MXPA04008073A (es) 2002-02-20 2004-11-26 Abbott Lab Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide.
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
NZ568700A (en) 2005-11-28 2012-03-30 Marinus Pharmaceuticals Solid stabilized particulate formulations comprising ganaxolone
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
CN104379578B (zh) 2012-03-19 2017-06-09 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
WO2013159095A1 (en) 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
DK2914248T4 (da) 2012-11-02 2024-01-02 Vertex Pharma Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015164160A1 (en) * 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
US9771341B2 (en) 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
BR112017024253A2 (pt) 2015-05-11 2018-07-24 Abide Therapeutics Inc métodos de tratamento de inflamação ou dor neuropática.
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
HUE056973T2 (hu) 2016-11-16 2022-04-28 H Lundbeck As MAGL inhibitor kristályos formája
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159581A (zh) * 2012-01-06 2014-11-19 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same

Also Published As

Publication number Publication date
EP3964503A1 (en) 2022-03-09
NZ753241A (en) 2021-06-25
CL2019001340A1 (es) 2019-10-04
EP3541807A1 (en) 2019-09-25
KR20190077561A (ko) 2019-07-03
BR112019010003A2 (pt) 2019-08-20
GEP20237559B (en) 2023-10-25
CN110291083A (zh) 2019-09-27
ES2900016T3 (es) 2022-03-15
RU2019116689A3 (cg-RX-API-DMAC7.html) 2021-02-26
SI3541807T1 (sl) 2022-01-31
US11993588B2 (en) 2024-05-28
WO2018093953A1 (en) 2018-05-24
ZA201903093B (en) 2020-11-25
JP7042548B2 (ja) 2022-03-28
HUE064559T2 (hu) 2024-03-28
US20200190063A1 (en) 2020-06-18
JP7350117B2 (ja) 2023-09-25
NI201900053A (es) 2019-10-30
UA124585C2 (uk) 2021-10-13
ES2966939T3 (es) 2024-04-25
MX389459B (es) 2025-03-20
EP3964503C0 (en) 2023-11-08
RU2019116689A (ru) 2020-12-17
EP3541807A4 (en) 2020-04-22
SMT202300494T1 (it) 2024-01-10
PL3541807T3 (pl) 2022-01-17
US11142517B2 (en) 2021-10-12
MY199386A (en) 2023-10-25
MX2022000249A (es) 2022-02-03
MA58133B1 (fr) 2024-02-29
SMT202100675T1 (it) 2022-01-10
US20220235037A1 (en) 2022-07-28
DK3541807T3 (da) 2021-12-06
HRP20231697T1 (hr) 2024-03-15
DOP2019000120A (es) 2019-09-30
CR20190242A (es) 2019-07-09
PH12019501068A1 (en) 2019-08-19
PL3964503T3 (pl) 2024-04-02
IL266548A (en) 2019-07-31
RS62665B1 (sr) 2021-12-31
KR102508739B1 (ko) 2023-03-09
CA3043610A1 (en) 2018-05-24
MX2019005767A (es) 2019-12-05
PE20191239A1 (es) 2019-09-16
AU2017361257B2 (en) 2022-02-10
RS65016B1 (sr) 2024-01-31
CY1124870T1 (el) 2022-11-25
LT3541807T (lt) 2021-12-27
EP3964503B1 (en) 2023-11-08
PT3541807T (pt) 2021-12-09
CN115093382A (zh) 2022-09-23
ECSP19035171A (es) 2019-05-31
JOP20190109B1 (ar) 2022-09-15
HRP20211863T1 (hr) 2022-03-04
JOP20190109A1 (ar) 2019-05-09
EP3541807B1 (en) 2021-09-29
MA46866A (fr) 2021-06-02
AU2017361257A1 (en) 2019-05-30
EA201991086A1 (ru) 2019-11-29
JP2022084717A (ja) 2022-06-07
CO2019005045A2 (es) 2019-05-31
MA46866B1 (fr) 2021-11-30
TN2019000151A1 (en) 2020-10-05
HUE056973T2 (hu) 2022-04-28
JP2019537596A (ja) 2019-12-26

Similar Documents

Publication Publication Date Title
CN110291083B (zh) Magl抑制剂的结晶形式
CA3006746C (en) Solid dispersions comprising a sgc stimulator
JP2025026857A (ja) 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CA2652300A1 (en) Pharmaceutical formulations of pimavanserin
EP3510023B1 (en) Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
CN113164439A (zh) 用于治疗或预防痛风或高尿酸血症的方法
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40069310B (en) A crystalline form of a magl inhibitor
RU2799564C2 (ru) Кристаллические формы ингибитора magl
HK40069310A (en) A crystalline form of a magl inhibitor
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
HK40009165B (en) A crystalline form of a magl inhibitor
HK40009165A (en) A crystalline form of a magl inhibitor
EA041551B1 (ru) Кристаллические формы ингибитора magl
NZ753241B2 (en) Crystalline forms of a magl inhibitor
JP2025524598A (ja) Ｓ１ｐ受容体モジュレーターの結晶形態
HK40056574B (zh) 用於治疗或预防痛风或高尿酸血症的化合物的晶型
HK40032224A (en) Crystalline forms of compounds for preventing or treating sensory hair cell death

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210712

Address after: Denmark valby

Applicant after: H. LUNDBECK A/S

Address before: California, USA

Applicant before: Lingbei La Jolla Research Center

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220617